A Unified Model of the GABA<sub>A</sub> Receptor Comprising Agonist and Benzodiazepine Binding Sites

Rikke Bergmann<sup>1,3</sup>, Kristine Kongsbak<sup>1,2</sup>, Pernille Louise Sørensen<sup>1</sup>, Tommy Sander<sup>3</sup>, Thomas Balle<sup>4,*</sup>

<sup>1</sup>Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, <sup>2</sup>National Food Institute, Technical University of Denmark, Søborg, Denmark, <sup>3</sup>Novo Nordisk A/S, Bagsvaerd, Denmark, <sup>4</sup>Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia

Abstract

We present a full-length α<sub>1</sub>β<sub>2</sub>γ<sub>2</sub> GABA receptor model optimized for agonists and benzodiazepine (BZD) allosteric modulators. We propose binding hypotheses for the agonists GABA, muscimol and THIP and for the allosteric modulator diazepam (DZP). The receptor model is primarily based on the glutamate-gated chloride channel (GluCl) from C. elegans and includes additional structural information from the prokaryotic ligand-gated ion channel ELIC in a few regions. Available mutational data of the binding sites are well explained by the model and the proposed ligand binding poses. We suggest a GABA binding mode similar to the binding mode of glutamate in the GluCl X-ray structure. Key interactions are predicted with residues α<sub>1</sub>R66, β<sub>2</sub>T202, α<sub>1</sub>T129, β<sub>2</sub>E155, β<sub>2</sub>Y205 and the backbone of β<sub>2</sub>S156. Muscimol is predicted to bind similarly, however, with minor differences rationalized with quantum mechanical energy calculations. Muscimol key interactions are predicted to be α<sub>1</sub>R66, β<sub>2</sub>T202, α<sub>1</sub>T129, β<sub>2</sub>E155, β<sub>2</sub>Y205 and β<sub>2</sub>F200. Furthermore, we argue that a water molecule could mediate further interactions between muscimol and the backbone of β<sub>2</sub>S156 and β<sub>2</sub>Y157. DZP is predicted to bind with interactions comparable to those of the agonists in the orthosteric site. The carbonyl group of DZP is predicted to interact with two threonines α<sub>1</sub>T206 and γ<sub>2</sub>T142, similar to the acidic moiety of GABA. The chlorine atom of DZP is placed near the important α<sub>1</sub>H101 and the N-methyl group near α<sub>1</sub>Y159, α<sub>1</sub>T206, and α<sub>1</sub>Y209. We present a binding mode of DZP in which the pending phenyl moiety of DZP is buried in the binding pocket and thus shielded from solvent exposure. Our full length GABA<sub>A</sub> receptor is made available as Model S1.


Introduction

γ-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system (CNS) as opposed to glutamic acid, which is the primary excitatory CNS-neurotransmitter (Figure 1). Structurally, the two compounds are similar, and in fact GABA is formed in vivo by decarboxylation of glutamate. GABA<sub>A</sub> receptors (GABA<sub>A</sub>Rs) are involved in a number of important functions such as cognition, learning, and memory and in disorders such as epilepsy, anxiety, schizophrenia, sleep disorders, and depression [1]. The GABA<sub>A</sub>Rs belong to the Cys-Loop receptor family that also includes nicotinic acetylcholine receptors (nAChRs), serotonin type 3 receptors (5-HT<sub>3</sub>Rs) and glycine receptors (GlyRs). All Cys-Loop receptors are homomeric or heteromeric assemblies of five subunits forming a central ion-conducting pore (Figure 2). The GABA<sub>A</sub>Rs and GlyRs conduct anions whereas nAChRs and 5-HT<sub>3</sub>Rs are cation selective. Each subunit is made up of an extracellular domain (ECD) consisting of mainly β-sheets, and a trans-membrane domain (TMD) consisting of four membrane spanning α-helices. GABA<sub>A</sub>R subunits include α<sub>1</sub>, β<sub>1</sub>, β<sub>3</sub>, γ<sub>1</sub>, δ, ε, π, θ, γ<sub>2</sub>, and the most abundant GABA<sub>A</sub>R subunit combination in the human CNS is the α<sub>1</sub>β<sub>2</sub>γ<sub>2</sub> subtype where the endogenous neurotransmitter GABA binds in each of the interfaces between β<sub>2</sub> and α<sub>1</sub> subunits (Figure 2). A modulatory site for benzodiazepine (BZD) like compounds is found in a homologous position between α<sub>1</sub> and γ<sub>2</sub> subunits.

Despite decades of research and a wealth of experimental and theoretical studies, the exact binding mode of key agonists including GABA is still unknown. The same is the case for the BZDs. Key agonists for the GABA binding site include the high affinity agonist muscimol [2,3] and the partial agonist THIP [4,5], which is a structurally restrainer muscimol analog (Figure 1). THIP was long in clinical trials for treatment of insomnia, but was discontinued. Still, the GABA<sub>A</sub>R agonist binding site is regarded a promising drug target and represents an intriguing alternative to the BZD binding site, which has long been the target for allosteric modulators including BZDs such as diazepam (Figure 1). BZDs are still one of the most prescribed classes of drugs for the treatment of insomnia, anxiety, and convulsions [6,7]. So far, drug discovery efforts have relied mainly on indirect structural insight from focused [8–12] or unified pharmacophore models recapitulating the structure-activity relationships (SAR) of compounds synthesized during more than fifty years of active medicinal chemistry research in the field [13,14]. Homology
models, on the other hand, have had little practical impact on the design process despite a number of models reported in the literature [15–25]. The models were mainly built using the homologous acetylcholine binding proteins (AChBPs) as templates. The AChBPs have supplied insight into a number of structural features of Cys-Loop receptors. The position of loops A–F (Figure 2) known from mutational studies to participate in ligand binding were established with the first AChBP structure [26]. A high degree of flexibility has later on been observed for the C-loop, which is a hair-pin shaped loop that embraces the orthosteric binding sites and shields from the solvent [27]. It was observed that depending on the type of ligand in the binding site, the C-loop either exists in a closed (agonist) conformation or an open (antagonist) conformation allowing large inhibitors to enter the binding site. This C-loop movement has also been speculated to be linked to the activation mechanism of Cys-Loop receptors [28].

Although, the AChBPs have proven valuable templates for modeling of nAChRs [26,29–32] they suffer from a lack of conservation of binding site residues with respect to GABA \(_A\) Rs, which makes them unsuitable as stand-alone templates for GABA\(_A\)R homology modeling. To compensate for the lack of conservation of binding site residues, we have recently reported a novel strategy for GABA\(_A\)R modeling utilizing experimental restraints and multiple templates including AChBPs from different species [27,33], a mouse \(\alpha_1\) nAChR subunit [34], and the bacterial orthologs from Gloeobacter violaceus (GLIC) [35] and Erwinia chrysanthemi (ELIC) [36] in the alignment generation and model building steps [37]. In particular, inclusion of the ELIC structure adds important conserved binding site residues to the pool of template structures. Using this strategy, a reliable model of the GABA\(_A\)R ECD with focus on the orthosteric ligand binding interface of the \(\alpha_1\beta_2\gamma_2\) GABA\(_A\)R in its non-activated (antagonized) state was obtained. The model was consistent with experimental data and capable of rationalizing the structure activity relationships (SAR) of a series of GABA\(_A\)R orthosteric antagonists [37].

With the recent release of atomic resolution structures of a eukaryotic glutamate gated chloride channel (GluCl) [38] from the nematode \(C.\) elegans, the molecular basis for modeling of pentameric ligand gated anion channels has improved considerably. The GluCl structure has an unprecedented high sequence identity compared to the GABA\(_A\)R; 30%, 36%, and 31% relating to \(\alpha_1, \beta_2\) and \(\gamma_2\) subunits, respectively, and even higher identities

![Figure 1. Some classical GABA\(_A\) receptor ligands.](https://example.com/image1)

GABA is the endogenous GABA\(_A\)R agonist, muscimol a classical high-affinity agonist and THIP a muscimol analogue. Although not a GABA\(_A\)R ligand, glutamate is included to illustrate the resemblance to GABA. Diazepam (DZP) belongs to the benzodiazepine class of compounds, which are allosteric GABA\(_A\) modulators. The DZP-NCS analogue attaches covalently to GABA\(_A\)Rs and is included for validation purposes.

![Figure 2. Illustration of the GABA\(_A\)R structural composition.](https://example.com/image2)

A) Top view showing the pentameric assembly of \(\alpha_1, \beta_2\) and \(\gamma_2\) subunits and the location of binding sites for GABA and BZDs; B) Side view illustrating the extracellular domain (ECD) where agonists and benzodiazepines bind and the transmembrane domain (TMD); C) Zooming in on a GABA binding site at the subunit interface between \(\beta_2\) and \(\alpha_1\) subunits, loop regions A–F mentioned in the text are shown (A: yellow, B: orange, C: red, D: purple, E: blue and F: pink).
with respect to the ligand binding cores (~48% in an 8 Å radius from glutamate in GluCl). The GluCl structure was crystallized in presence of its agonist glutamate and was captured in its presumed open state.

In this report we demonstrate the use of the GluCl structure as template for construction of a GABA\textsubscript{A} receptor homology model comprising both the ECD and TMD portions of the receptor. We show that when combined with the structure of the bacterial ELIC channel, a reliable GABA\textsubscript{A}R model based entirely on full length receptor X-ray structures can be obtained. The model is built in the open state with GABA in the two orthosteric binding sites between \(\beta_2\) and \(\gamma_2\) subunits. The BZD binding site between the \(\alpha_1\) and \(\gamma_2\) subunit is adapted to the positive allosteric modulator diazepam (DZP). The model is capable of explaining SARs, mutational data, and data from studies of covalent linking of a DZP-derivative to cysteine mutants of the receptor. Therefore, the validated model might also serve as a tool for structure guided design of new agonists and allosteric modulators and may form the link to interpretation of previously reported pharmacophore models [11,14,39] in a structural context.

Methods

Homology modeling

Templates, sequences and sequence alignment. The X-ray structure of GluCl co-crystallized with glutamate (PDB code 3RIF) [38] was used as primary template for homology modeling of the most abundant subtype of the GABA\textsubscript{A}R, \(\alpha_1\beta_2\gamma_2\). In a few important regions with low sequence identity to GluCl the bacterial homologue ELIC (PDB code 2VL0) [40], which has a 20% sequence identity to GluCl, was included as template as well. The extent to which each template structure was used is specified in Figure 3, in which the definitions for the general secondary structural elements of Cys-Loop receptors referred to throughout this paper are also indicated. The rationale for including ELIC as template in the areas highlighted in Figure 3 were the following: 1) In the \(\beta_1\) and \(\beta_2\) sheets the ELIC structure contains aromatic residues in positions 19 and 38 resembling those in the GABA\textsubscript{A}R; 2) In the \(\beta_6\)-\(\beta_7\)-loop (Cys-Loop) and in the \(\beta_7\) and \(\beta_{10}\) strands ELIC was included as template for the \(\beta_2\) subunit to capture information about the conformations of and interactions between GABA\textsubscript{A}R \(\beta_2\)E155 and \(\beta_2\)E207; 3) In the two M2–M3-loop ELIC was included as template due to the presence of Pro residues in homologous positions.

The sequence alignment was obtained following the procedure reported by Sander et al. [37] First, a structural alignment of the two template structures was generated using Pymol 1.3 [41]. Subsequently, all human GlyR \(\alpha\)-subunits and all human GABA\textsubscript{A}R subunits were aligned to the GluCl sequence as profile alignments with iteration on the last alignment using ClustalX v. 2.0.12 [42]. The GlyR \(\alpha\)-subunits represent the closest human homologs to GluCl and were included to aid identification of semi-conserved motifs. In three regions, namely, 1) in and after the N-terminal \(\alpha\)-helix, 2) in loop F, and 3) in loop C, manual adjustments of the generated alignment were performed to ensure proper alignment of conserved motifs. 1) In the N-terminal \(\alpha\)-helix the motif represented by the GABA\textsubscript{A} \(\alpha_1\) sequence ILDRL1LGDYDNRLRP was misaligned by ClustalX due to the presence of insertions in the GlyR \(\alpha\)-subunit sequences and the GABA\textsubscript{A}R \(\rho\)-subunit sequences. Therefore, this motif was reestablished as described by Sander et al. [37] 2) In loop F varying sequence lengths and low sequence identity resulted in a poor alignment and many gaps. We identified a hydrophobic-X-hydrophobic motif (corresponding to YYV in the GABA\textsubscript{A}R \(\alpha_1\)-subunit), forming a short \(\beta\)-strand of three residues in GluCl, ELIC, the bacterial ion channel GLIC (PDB ID: 2B7O) [43] as well as in other sequences in the orthosteric binding sites between chains A, B and C, D. Then the \(\alpha\)-carboxylic acid moiety was deleted from the glutamate ligands, resulting in a GluCl template structure with GABA in the two orthosteric binding sites between chains A, B and C, D.

Model building, evaluation and selection. The program MODELLER 9n7 [44] was used for homology modeling using the “automodel class”, which includes no other restraints than spatial restraints gathered from the sequence alignment. 100 models were generated, and the refinement level “refine-slow” was applied. GABA molecules were modeled into the two \(\beta_2\)-\(\gamma_2\) subunit interfaces in the GABA\textsubscript{A}R receptor model as rigid bodies.

The final model selection was performed according to the consensus scoring approach described by Sander et al. [37] using the ProSA z-score [45], the energy according to the OPLS 2001 force field [46,47] as implemented in Maestro [48], and the MODELLER built in scoring functions, molidf and DOPE, score [44]. The consensus 10 best scoring models were assessed visually for physico-chemical requirements such as packing of hydrophobic residues in hydrophobic environments and solvent exposure of charged residues. Also, the interactions between the modeled GABA molecule and the receptor model were assessed as part of the selection criteria.

Model refinement

The selected model was subjected to the protein preparation wizard in Maestro [48], which adds hydrogen atoms, assigns bond orders, creates disulphide bonds and samples hydrogen bond networks. Furthermore, the protein preparation wizard assesses the protonation state of His, Lys, Arg, Glu, and Asp. As is seen in the GluCl structure E293 interacts with R245 and D316, indicating that this residue exists in its protonated form. Therefore, the corresponding five Glu residues (two \(\alpha_1\)E302, two \(\beta_2\)E298, and one \(\gamma_2\)E313) in the homology model, which also coordinates to Arg and Asp were protonated. The protein preparation wizard and the PROPKA web server [49–51] further supported this assessment. All other residues were kept at their standard protonation states (neutral His, protonated Lys and Arg and deprotonated Glu and Asp). Finally, an energy minimization with a flat-bottomed Cartesian constraint and a convergence threshold set to an RMSD of 0.3 Å was performed.

The model was further refined as follows: 1) The rotamer state of \(\gamma_2\)R66 (in chain D) was optimized for optimal hidentate interactions with GABA using the side chain refinement tool in Prime [52]; 2) Hydrogen bond networks between the GABA molecules and the receptor model were manually optimized by selecting appropriate rotamers of \(\gamma_2\)T129 similar to the homologous S121 in the GluCl structure; 3) Loop A (residues 99–102) in the BZD site carrying Cys-Loop receptors. 4) Finally, we truncated the M3–M4 intracellular loop and inserted an AGT tripeptide according to the GluCl structure. The manually adjusted alignment is reported in Figure 3.
sampling protocol in Prime [52] in order to obtain an orientation of $\alpha_1$, $\beta_2$, and $\gamma_2$-GABA$_A$R subunits. The GluCl sequence was used as template for homology modeling throughout the GABA$_A$R subunits, and ELIC was included as a template in the regions marked with blue boxes. The secondary structure deduced from the X-ray structure of GluCl is shown above the alignment (red shapes denote $\alpha$-helices, and green arrows denote $\beta$-strands), whereas historically assigned loop regions are indicated below the alignment. In the GluCl structure the M3–M4 intracellular loop of GABA$_A$R sequences was replaced by an AGT tri-peptide linker. Residues comprising the binding sites (within 8 Å of Glu in the GluCl structure and pointing towards the binding site) are colored pink (Glu and GABA binding site) and cyan (BZD binding site). Binding site residues conserved with respect to the templates are indicated as follows: + conserved in both GABA and BZD binding sites; * conserved in the BZD binding site. For details on calculation of binding site sequence identities see Figure S1.

doi:10.1371/journal.pone.0052323.g003

Figure 3. Alignment of protein sequences from GluCl, GLIC, ELIC and the human $\alpha_1$, $\beta_2$, and $\gamma_2$-GABA$_A$R subunits. The GluCl sequence was used as template for homology modeling throughout the GABA$_A$R subunits, and ELIC was included as a template in the regions marked with blue boxes. The secondary structure deduced from the X-ray structure of GluCl is shown above the alignment (red shapes denote $\alpha$-helices, and green arrows denote $\beta$-strands), whereas historically assigned loop regions are indicated below the alignment. As in the GluCl structure the M3–M4 intracellular loop of GABA$_A$R sequences was replaced by an AGT tri-peptide linker. Residues comprising the binding sites (within 8 Å of Glu in the GluCl structure and pointing towards the binding site) are colored pink (Glu and GABA binding site) and cyan (BZD binding site). Binding site residues conserved with respect to the templates are indicated as follows: + conserved in both GABA and BZD binding sites; * conserved in the BZD binding site. For details on calculation of binding site sequence identities see Figure S1.

doi:10.1371/journal.pone.0052323.g003

Figure 3. Alignment of protein sequences from GluCl, GLIC, ELIC and the human $\alpha_1$, $\beta_2$, and $\gamma_2$-GABA$_A$R subunits. The GluCl sequence was used as template for homology modeling throughout the GABA$_A$R subunits, and ELIC was included as a template in the regions marked with blue boxes. The secondary structure deduced from the X-ray structure of GluCl is shown above the alignment (red shapes denote $\alpha$-helices, and green arrows denote $\beta$-strands), whereas historically assigned loop regions are indicated below the alignment. As in the GluCl structure the M3–M4 intracellular loop of GABA$_A$R sequences was replaced by an AGT tri-peptide linker. Residues comprising the binding sites (within 8 Å of Glu in the GluCl structure and pointing towards the binding site) are colored pink (Glu and GABA binding site) and cyan (BZD binding site). Binding site residues conserved with respect to the templates are indicated as follows: + conserved in both GABA and BZD binding sites; * conserved in the BZD binding site. For details on calculation of binding site sequence identities see Figure S1.

doi:10.1371/journal.pone.0052323.g003

Figure 3. Alignment of protein sequences from GluCl, GLIC, ELIC and the human $\alpha_1$, $\beta_2$, and $\gamma_2$-GABA$_A$R subunits. The GluCl sequence was used as template for homology modeling throughout the GABA$_A$R subunits, and ELIC was included as a template in the regions marked with blue boxes. The secondary structure deduced from the X-ray structure of GluCl is shown above the alignment (red shapes denote $\alpha$-helices, and green arrows denote $\beta$-strands), whereas historically assigned loop regions are indicated below the alignment. As in the GluCl structure the M3–M4 intracellular loop of GABA$_A$R sequences was replaced by an AGT tri-peptide linker. Residues comprising the binding sites (within 8 Å of Glu in the GluCl structure and pointing towards the binding site) are colored pink (Glu and GABA binding site) and cyan (BZD binding site). Binding site residues conserved with respect to the templates are indicated as follows: + conserved in both GABA and BZD binding sites; * conserved in the BZD binding site. For details on calculation of binding site sequence identities see Figure S1.

doi:10.1371/journal.pone.0052323.g003

Ligand docking and binding site characterization

GABA, muscimol, and THIP were created in their ionized states in Maestro 9.2 [53] followed by conformational searches with MacroModel 9.9 (default settings) [54]. The global energy minimum conformations were identified and used as input conformations for docking. The agonists were docked into the orthosteric binding site between chains A and B using the Glide Induced Fit Docking (IFD) protocol [55,56] and the Extra Precision (XP) scoring function [57]. By default the IFD procedure allows amino acid side chains to adapt to the docked ligand in a 5 Å sphere. Docking poses were selected based on compliance with mutational data (Table 1) and common interaction patterns in the binding site. Finally, selected ligand poses including residues in an 8 Å sphere were energy minimized to convergence using MacroModel 9.9.

The program GRID [58,59] was used to characterize the nonbonded water interaction properties of the vacant binding pocket between chains A and B (GABA$_A$ site) of the refined model using the water probe (OH2). A grid spacing of 0.33 Å was used and all other settings were kept at their default values.

Quantum mechanical (QM) calculations was performed using Jaguar 7.8 [60]. For muscimol, a relaxed coordinate scan was performed to determine conformational energies when varying the amino-methyl side chain dihedral angle in a step size of 10° between 0°–180°. The Poisson-Bolzmann aqueous solvation model
A Unified Model of the GABA<sub>A</sub> Receptor

Table 1. Overview of mutations affecting the function of the GABA<sub>A</sub>R or the binding of orthosteric ligands.

<table>
<thead>
<tr>
<th>Residue</th>
<th>Proposed function/feature</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Structural features</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β&lt;sub&gt;1&lt;/sub&gt;E153, β&lt;sub&gt;2&lt;/sub&gt;K196</td>
<td>Intra-subunit salt bridges important for receptor function.</td>
<td>[112]</td>
</tr>
<tr>
<td>Ligand-binding features</td>
<td></td>
<td></td>
</tr>
<tr>
<td>α&lt;sub&gt;1&lt;/sub&gt;F64</td>
<td>Affects binding of bicuculline and gabazine and SCAM identified residue to be part of binding site.</td>
<td>[84–86,113]</td>
</tr>
<tr>
<td>α&lt;sub&gt;1&lt;/sub&gt;R66</td>
<td>Identified by SCAM to be part of binding site.</td>
<td>[84,86]</td>
</tr>
<tr>
<td>α&lt;sub&gt;1&lt;/sub&gt;L117</td>
<td>Identified by SCAM to be part of binding site. Also binding of gabazine is affected.</td>
<td>[89]</td>
</tr>
<tr>
<td>α&lt;sub&gt;1&lt;/sub&gt;R119</td>
<td>Predicted by SCAM to line binding site. Mutation to Lys results in 180 fold reduced EC&lt;sub&gt;50&lt;/sub&gt; for GABA and inability of muscimol and gabazine to bind.</td>
<td>[89,114]</td>
</tr>
<tr>
<td>α&lt;sub&gt;1&lt;/sub&gt;T129</td>
<td>Predicted by SCAM to line binding site.</td>
<td>[85,89]</td>
</tr>
<tr>
<td>α&lt;sub&gt;1&lt;/sub&gt;R131</td>
<td>Predicted by SCAM to line binding site.</td>
<td>[89]</td>
</tr>
<tr>
<td>β&lt;sub&gt;2&lt;/sub&gt;E155</td>
<td>Cys mutation gives rise to spontaneously open channel. Predicted to be connected to gating and ligand binding.</td>
<td>[76]</td>
</tr>
<tr>
<td>β&lt;sub&gt;2&lt;/sub&gt;Y157</td>
<td>Mutagenesis to Cys, Asn, Phe, and Ser indicate that this residue must be aromatic. Artificial amino acid mutagenesis does not indicate pi-cation interaction with this residue.</td>
<td>[76,81,91]</td>
</tr>
<tr>
<td>β&lt;sub&gt;2&lt;/sub&gt;F200</td>
<td>Cys mutation significantly affects gabazine affinity as well as receptor activation.</td>
<td>[82]</td>
</tr>
<tr>
<td>β&lt;sub&gt;2&lt;/sub&gt;S201</td>
<td>Cys mutation affects gabazine affinity as well as receptor activation.</td>
<td>[82]</td>
</tr>
<tr>
<td>β&lt;sub&gt;2&lt;/sub&gt;T202</td>
<td>Ala and Cys mutations renders receptor essentially inactive. Ser mutation is accepted but decreases EC&lt;sub&gt;50&lt;/sub&gt; slightly.</td>
<td>[81,82]</td>
</tr>
<tr>
<td>β&lt;sub&gt;2&lt;/sub&gt;G203</td>
<td>Cys mutation severely affects affinity of gabazine and activation of the receptor.</td>
<td>[82]</td>
</tr>
<tr>
<td>β&lt;sub&gt;2&lt;/sub&gt;Y205</td>
<td>Crucial residue that must be aromatic. Mutations to Ser and Asn renders the receptor inactive, and mutation to Cys affects both gabazine binding and receptor activation very severely.</td>
<td>[81,82]</td>
</tr>
<tr>
<td>β&lt;sub&gt;2&lt;/sub&gt;R207</td>
<td>Affects GABA binding and un-binding rates. Predicted to be part of binding site.</td>
<td>[78,82]</td>
</tr>
</tbody>
</table>

All data in the table are in agreement with our GABA<sub>A</sub>R model.
doi:10.1371/journal.pone.0052323.t001

[61] and otherwise default settings were selected (B3LYP/6-31G<sup>∗∗</sup>). Gas-phase energies were extracted from the results in order to consider only the steric energies.

The docking procedure described for the agonists was also attempted for DZP at the BZD site, but none of the obtained poses could be rationalized by experimental data. DZP was docked using its assumed bioactive conformation as input for docking [62–66]. QM partial charges were calculated using Jaguar 7.6 default settings. Subsequently, DZP was manually docked to the BZD binding site according to experimental evidence: Docked DZP should 1) have the C1-substituent positioned in the vicinity of or pointing towards α<sub>1</sub>H101, α<sub>2</sub>N102 [67], α<sub>1</sub>G157, α<sub>1</sub>V202, and α<sub>1</sub>V211 [68], 2) have the C-3 atom positioned in the vicinity of or directed towards α<sub>1</sub>S205 and α<sub>2</sub>T206 [69], 3) have the N-methyl substituent directed towards an exit from the binding cavity [70], and 4) have the pending phenyl ring positioned in a lipophilic cavity [71,72]. Following manual positioning of DZP, the α<sub>1</sub>γ<sub>2</sub> interface was allowed to adapt to DZP using the side chain prediction tool in Prime in which backbone and residue sampling within 4 Å of DZP was performed. As a final step, Prime performs a minimization of the complex, the docked ligand and the surrounding residues in question (backbone and side chains). The protein and the ligand were thus allowed to adapt to each other. The final model was further validated using 1) mutational studies from the literature (Table 2), 2) in silico covalent docking of a Cys-reactive DZP derivative, and 3) assessment of SAR data from the literature in a structural context.

As a validation of the DZP binding mode, the Cys-reactive BZD derivative DZP-NGS [67,68,73,74] (Figure 1) was covalently docked to an α<sub>1</sub>H101C variant of the homology model using the “covalent docking” module in Prime. The covalent docking module works by eliminating two atoms in order to form a new bond between the reacting molecules/species. Since Prime cannot handle simultaneous reduction of a double bond and formation of a new bond, the isothiocyanato group of DZP-NCS was reduced to a methanethioamide group prior to submission of the job. The thiol-hydrogen was defined as the leaving receptor atom. The conformation of the attachment residue was sampled and all other residues were kept fixed.

Finally, a 48 ns molecular dynamics simulation was performed to assess the stability of the final GABA<sub>A</sub>R model. Details are supplied as Model S1.

Results and Discussion

With the improved structural templates available from efforts in structural biology it is now possible to build α<sub>1</sub>β<sub>2</sub>γ<sub>2</sub> GABA<sub>A</sub>R models based entirely on full length receptor templates. We have created a full-length α<sub>1</sub>β<sub>2</sub>γ<sub>2</sub> GABA model mainly based on the glutamate bound GluCl X-ray structure and partly using the bacterial Cys-Loop homolog ELIC as an additional template. The model has been optimized in the GABA and BZD binding sites for the agonists GABA, muscimol and THIP and the modulator diazepam. The GluCl X-ray structure with glutamate bound was crystallized in an open state with a negatively charged ion in the lower part of the TMD [38]. The ELIC structure, on the other hand, was crystallized in a putatively closed state in absence of a bound ligand [36]. Since only a few residue positions in our model...
have been modeled based on the ELIC structure, the overall architecture of the α1β2γ2 GABA model is obtained from the GluCl structure. Therefore, we regard our model as being in the open state.

Model assessment

The pentameric GABA<sub>A</sub>R α1β2γ2 ECD-TMD homology model comprised 1676 residues distributed with 335, 334, and 333 residues in α1, β2, and γ2 GABA<sub>A</sub>R subunits, respectively. The selected model had good backbone geometry with 98.8% of the residues in favorable or additionally allowed regions in the Procheck v. 3.5.4 Ramachandran plot [75]. All residues in disallowed regions in the Ramachandran plot were situated in solvent exposed loop regions distant to the binding site. The ProSA z-scores for the selected homology model were within the accepted area for X-ray structures from the PDB. Furthermore, stability of the model was assessed by a 48 ns molecular dynamics calculation which showed essentially no drift after termination of the equilibration protocol (see Figure S2).

Validation by mutational data. Both the GABA and BZD binding sites have been heavily investigated by site-directed mutagenesis (Tables 1 and 2). Among these mutations, some have been used to suggest which residues line the binding sites, which residues interact directly with different ligands, and which are regarded as important structural features of the receptor. These experimental data, including those listed in Tables 1 and 2 that were not directly imposed during model refinement, are explainable by our homology model with the suggested poses of GABA and DZP as described below.

Table 2. Overview of mutations affecting the function of the GABA<sub>A</sub>R or the ability of BZD binding site ligands to bind to the BZD binding site.

<table>
<thead>
<tr>
<th>Residue</th>
<th>Proposed function/feature</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>α1F99</td>
<td>May be involved in π–π stacking or might in some other way interact directly with ligands of the BZD type.</td>
<td>[67,96]</td>
</tr>
<tr>
<td>α1H101</td>
<td>May be involved in π–π stacking or might in some other way interact directly with ligands of the BZD type.</td>
<td>[73,97,116]</td>
</tr>
<tr>
<td>α1Y159</td>
<td>Mutation to Ala, Cys or Ser severely affects binding affinity of BZDs. Residue lines the binding site.</td>
<td>[67,68,98]</td>
</tr>
<tr>
<td>α1G200</td>
<td>This residue lines a distal part of the binding site</td>
<td>[96,104,105,116]</td>
</tr>
<tr>
<td>α1V202</td>
<td>This residue lines a distal part of the binding site</td>
<td>[96,104]</td>
</tr>
<tr>
<td>α1T206</td>
<td>Mutation to Ala, Val, and Cys severely affects binding affinity of BZD-site ligands.</td>
<td>[68,69,99,102,105]</td>
</tr>
<tr>
<td>α1G207</td>
<td>Mutation to Cys severely affects binding affinity of flunitrazepam.</td>
<td>[68]</td>
</tr>
<tr>
<td>α1Y209</td>
<td>Aromatic functionality of the residue at this position is required for high-affinity binding of BZD binding site ligands.</td>
<td>[96,98,99]</td>
</tr>
<tr>
<td>γ2F77</td>
<td>Aromatic functionality of the residue at this position is required for high-affinity binding of BZD binding site ligands.</td>
<td>[100–102]</td>
</tr>
<tr>
<td>γ2M130</td>
<td>This residue lines the binding site</td>
<td>[96,102]</td>
</tr>
</tbody>
</table>

Covalently modified mutants

<table>
<thead>
<tr>
<th>Residue</th>
<th>Proposed function/feature</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>α1G157</td>
<td>7-NCS-derivatives of imidazo-BZDs react covalently with Cys-mutants of this residue suggesting the 7-position of imidazo-BZDs points towards this residue.</td>
<td>[68]</td>
</tr>
<tr>
<td>α1Y159</td>
<td>The NCS-derivative of imidazo-BZD does not react covalently with Cys-mutants of this residue. 7-substituent is not directed towards this residue.</td>
<td>[68]</td>
</tr>
<tr>
<td>α1V202</td>
<td>7-NCS-derivatives of imidazo-BZDs react covalently with Cys-mutants of this suggesting the 7-position of imidazo-BZDs points towards this residue.</td>
<td>[68]</td>
</tr>
<tr>
<td>α1S205</td>
<td>The 3-NCS-derivative of flunitrazepam reacts covalently with the Cys-mutant, forming a constitutively positively modulated receptor.</td>
<td>[69]</td>
</tr>
<tr>
<td>α1S206</td>
<td>The 3-NCS-derivative of flunitrazepam reacts covalently with the Cys-mutant, forming a constitutively positively modulated receptor.</td>
<td>[69]</td>
</tr>
<tr>
<td>α1V211</td>
<td>7-NCS-derivatives of imidazo-BZDs react covalently with Cys-mutants of this residue suggesting the 7-position of imidazo-BZDs points towards this residue.</td>
<td>[68]</td>
</tr>
</tbody>
</table>

All data in the table is in agreement with our GABA<sub>A</sub>R model.

doi:10.1371/journal.pone.0052323.t002

The binding site of the GABA<sub>A</sub>R consists of residues that directly interact with ligands of the BZD type as allosteric modulators or are involved in the formation of ionic channels. However, there is no clear evidence for the involvement of residues in the binding site that are not directly interacting with the ligands. The GABA<sub>A</sub>R orthosteric binding site apparently resembles the GluCl glutamate binding site to a large extent. However, there are

Agonist binding model

GABA. The X-ray structure of GluCl with glutamate bound presents a good indication of how GABA would bind to the GABA receptors. Our α1β2γ2 GABA model confirms that a similar GABA binding mode interacts well with the receptor and is in agreement with the experimental mutational data presented in Table 1. In this binding mode GABA forms salt bridges with α1R66 and β2E155 and hydrogen bonds with α1T129, β2T202, and the backbone of β2S156. Finally, there is a π-cation interaction with β2Y205. The GABA binding mode from our docking study is illustrated in Figure 5A. As described in the methods section GABA was modeled into the binding pockets of our receptor model as rigid bodies, which allowed space for GABA in the binding site. However, hydrogen bonding network was not optimized in the modeling process, hence, a few side chains needed adjustments as described in the methods section.

The GABA<sub>A</sub> orthosteric binding site apparently resembles the GluCl glutamate binding site to a large extent. However, there are
a few crucial differences. Newell et al. [76] identified β2E155 to be vital for GABA\_A ligand binding and channel gating. This residue is lacking in the GluCl receptor, but is present in ELIC (Figure 4A), a receptor, which is known to be activated by e.g. GABA [77], an important reason for including the ELIC structure as modeling template. The position of β2E155 in our receptor model is in perfect hydrogen bonding distance to the protonated amine of GABA, thereby forming a salt bridge deeply buried in the pocket and surrounded by a number of aromatic residues (so-called aromatic box). β2E155 is flanked by β2R207 intruding from outside the pocket. This residue has also been investigated experimentally and shown to affect GABA binding and un-binding [78], which makes sense if GABA binds as predicted here, since there is a clear electrostatic interaction between β2R207 and GABA through β2E155. Two other important residues that are non-conserved between GluCl and GABA\_A, but present in ELIC, are the β2F200 (C-loop) and ζ1F64 (D-loop). They serve as components of the aromatic box, taking part in shielding the positive charge in an enclosure of aromatic planes.

When GABA was re-docked into the binding site, a similar binding pose was identified (Figure 5A). This extended conformation of GABA has previously been determined by X-ray crystallography [79,80] and by conformational search found as one of several low energy conformations. However, the GABA alkyl chain is quite flexible, and it is likely that it is not entirely fixed in the protein bound state. The distance between the two charges is approximately 5 Å in the identified pose. However, even if the GABA alkyl chain should be slightly bent, resulting in a shorter inter-charge distance, optimal interactions can be obtained in the binding pocket by GABA interacting with the backbone carbonyl of β2Y157 in place of β2S156. Indeed, previous pharmacophore models disagree on which should be the exact charge-charge distance in GABA\_A agonists. However, it has generally been proposed to be in the range 4–5 Å [11] and in fact, our GABA\_A model predicts that agonist with different inter-charge distances (4–5 Å) may bind equally well to the receptor. Apart from the salt bridge to β2E155, the positive charge of GABA is further surrounded by the aromatic ring of β2Y205 and makes a hydrogen bond to the backbone β2S156 (B-loop) similar to glutamate in the GluCl template structure. Mutational data show that β2Y205 is crucial for binding gabazine, a selective, competitive GABA\_A antagonist, and for channel gating and that this residue must be aromatic for the receptor to be functional (Table 1) [81–83]. The carboxylic acid of GABA is fixed between β2 and ζ1 subunits by a bidentate interaction with ζ1R66 and hydrogen bonds with the two threonines β2T202 (C-loop) and ζ1T129. Again, these interactions make perfect sense in the light of published experimental data (Table 1). Mutations of ζ1T202 have a crucial impact on GABA activation of the GABA\_A receptor. Mutation to Ala or Cys renders the receptor virtually inactive, while some function is retained with a ζ1T202S mutation [81,82]. ζ1R66C mutations have shown a 300–500 fold decrease in EC50 and the residue was shown by the substituted cysteine accessibility method (SCAM) to be part of the binding pocket [84,85]. This residue has long been suspected to interact with the carboxylic acid of GABA [84,86–88]. However, ζ1R119 (in GABA\_A) and ζ1R131 and β2R207 have also been hypothesized to perform this interaction [78,87,89]. Based on the GluCl X-ray structure and available mutational data, the evidence for ζ1R66 to be the arginine interacting with the GABA carboxylic acid is quite strong. β2R207 interacts with GABA through β2E155 as discussed above. In our model ζ1R119 (conserved in GluCl) has an important structural role, as it links the ζ-subunit to the C-loop of the β-subunit (hydrogen bond to the backbone of β2T202) thereby forming a “roof” on top of the agonist binding site as well as an enforced closed state of the C-loop. A closed C-loop has long been regarded necessary for obtaining the active state of Cys-Loop receptors [27,43,90]. ζ1R131 is found lining the back wall of the binding site behind ζ1F64, where it interacts with ζ1D62 and the backbone of β2D101. Nevertheless, the flexible ζ1R131 could also reach β2Y97 to form a π-cation interaction. This residue was identified by Padgett et al. [91] to participate in a π-cation interaction in the GABA\_A receptors and they suggested that the cation should originate from the GABA molecule. However, based on our model a π-cation interaction between GABA and β2Y97 is unlikely. Indeed, it has generally caused difficulty to generate a

Figure 4. Conserved template residues. The figure shows residues that are conserved or homologous to GABA\_A binding site residues from the GluCl X-ray structure (PDB ID 3RIF) as grey sticks and the bacterial Cys-Loop receptor homolog, ELIC (PDB ID 2VL0) as purple sticks. Glutamate as co-crystallized with GluCl is shown in yellow, where the structure corresponding to GABA is shown as sticks and the ζ-carboxylic acid removed prior to homology modeling is shown as lines. A) GABA binding site and B) BZD binding site. doi:10.1371/journal.pone.0052323.g004
GABA<sub>A</sub> receptor model with the aromatic ring of β<sub>2</sub>Y97 facing the binding pocket, which has not changed with the improved template GluCl [37,91]. The authors suggested α<sub>1</sub>R131 as an alternative cation source in the binding site, and this would fit our model. The mutational consequences of β<sub>2</sub>Y97C and α<sub>1</sub>R131C could instead originate from perturbation of the activation mechanism.

**THIP and muscimol.** The docked poses of the other hallmark agonists THIP and muscimol are illustrated in Figure 5B–C. Poses with similar interactions as described above for GABA were identified, however, with some differences as discussed below.

The rigid THIP is able to make the same interactions as GABA. The 3-hydroxy-isoxazole moiety, a bio-isostere of the carboxylic acid in GABA, interacts with α<sub>1</sub>R66, β<sub>2</sub>T202 and α<sub>1</sub>T129 similar to GABA. Furthermore, the protonated amine forms a salt bridge to β<sub>2</sub>E155 and a pi-cation interaction with the important β<sub>2</sub>Y205.

The pose obtained for muscimol at first seemed erroneous, due to a slight displacement of the charged amine compared to GABA and THIP (Figure 5C). In this pose the positive charge is tucked in between the two C-loop aromatic residues β<sub>2</sub>Y205 and β<sub>2</sub>F200, however, the salt bridge to β<sub>2</sub>E155 is retained. The acidic moiety of the 3-hydroxy-isoxazole was perfectly placed similar to THIP and GABA. Therefore, the only difference compared to the GABA receptor interactions is a π-cation interaction with β<sub>2</sub>F200 instead of a backbone interaction to the B-loop. Despite numerous docking attempts and efforts to manually reposition muscimol to a pose similar to GABA and THIP, when energy minimized, the muscimol amino-methyl side chain kept “flipping” back. A dihedral drive using QM calculations revealed that the reason was a preferred torsional angle (O-C-C-N) of the muscimol amino-methyl side chain at ca. 45° (Figure 6). If both charges of muscimol were to overlay with the charges of GABA in the bound state, it would result in a torsional angle of 90° which would result in a conformational energy penalty of ≈3 kcal/mol (Figure 6). Such a high conformational energy is unlikely for a high affinity ligand as muscimol (K<sub>i</sub> = 6 nM), which binds to GABA<sub>A</sub> receptors with an even higher affinity than GABA itself (K<sub>i</sub> = 18 nM) [92,93]. The identified binding mode of muscimol depicted in Figure 5C has an O-C-C-N torsional angle of ca. 60°, which corresponds to a conformational energy penalty of ≈0.6 kcal/mol. Still, we were puzzled if no interaction with a B-loop backbone carbonyl should take place when muscimol binds. This is a generally accepted binding feature of Cys-Loop receptor agonists [26,27,94]. A GRID interaction energy calculation using the water probe (OH2) prior to optimization of the orthosteric receptor pocket revealed a region of high specificity for a water molecule (<−11 kcal/mol) next to the B-loop backbone carbonyls from β<sub>2</sub>S156 and β<sub>2</sub>Y157 (Figure 7A). When placing muscimol and a water molecule in the orthosteric binding site, it was found that hydrogen bonding distances were optimal and allowed muscimol a more extensive bonding pattern within the binding site than GABA. When also including the GABA binding pose, it was apparent that the GABA positive charge and the water molecule occupy the same region in the pocket (Figure 7B). We therefore propose that muscimol binds in concert with a water molecule as illustrated in Figure 7A resulting in a low conformational energy penalty and optimal interactions with the GABA<sub>A</sub> orthosteric binding pocket.

**BZD binding model**

As described in the methods section DZP was manually positioned in a binding mode (Figure 8) satisfying the listed

---

**Figure 5. Agonist binding modes determined by induced fit docking.** A) GABA (green), B) THIP (pink) and C) muscimol (cyan) are shown in the orthosteric binding site at the interface between the β<sub>2</sub> subunit (teal) and the α<sub>1</sub> subunit (smudge). doi:10.1371/journal.pone.0052323.g005

**Figure 6. Conformational energy profile for dihedral drive of the amino-methyl side chain of muscimol.** B3LYP/6-31G** energies. doi:10.1371/journal.pone.0052323.g006
criteria deduced from experimental literature data followed by optimization of side chains in the binding pocket. The resulting model agrees to a large extent with the binding mode of DZP, recently described by Richter et al. [95] despite being built on different templates and is further in agreement with available mutational data (Table 2) indicating that residues a1F99, [67,96] a1H101, [73,97] a1Y159, [96,98] a1Y209, [96,98,99] y2F77, [100–102] and y2M130 [96,102] line the binding pocket. As was the case for the GABA othosteric binding site, the GluCl template contributes to the homology model with a higher similarity than the previously available templates. Furthermore, the ELIC X-ray structure adds information about a few BZD binding site residues (γ2Y58 and γ2F77) lacking in the GluCl structure (Figure 4B). In brief, the obtained binding mode of DZP orients the chlorine atom of DZP towards a1H101 and positions it underneath the C-loop pointing towards the base of the C-loop (Figure 6). The pending phenyl ring is positioned in a narrow cavity between a1F99 (A-loop), a1Y159 (B-loop), and γ2F77 (D-loop) in the bottom of the binding site shielded from solvent exposure. The carbonyl is positioned in a manner similar to the carboxylic acid of GABA in the othosteric binding site. It links the two subunits at the interface by hydrogen bonds to a1T206 (C-loop) and γ2T142 (D-loop). Finally, the polarized N-methyl group is situated near the C-loop enabling polar contacts with a1T206, a1Y209 and the backbone of a1Y159 (Figure 8).

BZD pharmacophore models based on SAR data have predicted a lipophilic pharmacophoric feature (in the traditional BZD pharmacophore terminology named L1) to be an essential part of BZDs [71,103]. In DZP this feature corresponds to the fused aromatic ring system, which in the model is buried beneath the C-loop and shielded from solvent by the hydrophobic residues a1V202, γ2 of a1T206, a1Y209, and a1V211. a1V202 was predicted by mutational studies to line the binding site [96,104] and a1T206 and a1Y209 are both essential for ligand binding to the BZD site [88,69,96,98,99,102,103]. SAR studies [71,103] state that the pharmacophoric feature, L1, should be accommodated in a narrow cavity that does not tolerate substitution at other positions than that corresponding to C-7 in DZP (see Figure 1). Our proposed DZP binding mode comply well with this notion, since substitution at positions C-8 and C-9 would lead to steric interference with backbone atoms of the C-loop. Substitution at the C-6 position would lead to steric clashes with a1H101 and γ2F99 explaining why this is not tolerated. [71,72] However, the cavity, in which the DZP C-7 substituent (pharmacophoric feature L2), the chlorine atom, is positioned, has to be spacious enough to accommodate larger substituents (e.g. a nitro group as seen in flunitrazepam) [72]. This is indeed the case in our model. The position of the pharmacophoric feature, L2, is further supported by studies of covalent labeling of cysteine mutants [67,69]. In these studies, a DZP derivative, where the chlorine atom is substituted to a cysteine-reactive isothiocyanate group (DZP-NCS, Figure 1), is covalently linked to cysteine mutants of the receptor. Covalent labeling of a1H101C leads to a constitutively positively allosterically modulated receptor, which indicates that the ligand is covalently attached in an orientation matching the orientation of DZP in its bioactive conformation. We replicated this study in silico through covalent docking of DZP-NCS and obtained a pose complying with experimental data (Table 2) and resembling the otherwise established binding mode (Figure 8B) among the top scoring poses. As can be seen from the overlay of the docked DZP and the covalently attached DZP-NCS, the two ligands obtain similar binding modes, the primary difference being caused by a slight rotation of the scaffold of DZP-NCS to allow for covalent attachment of DZP-NCS. Furthermore, labeling of a2S205C, a1T206C mutants by a C-3 DZP-NCS probe strongly indicates the C-3 of DZP-NCS to point towards the tip of the C-loop [69]. Labeling with an imidazobenzodiazepine-NCS derivative of the partial negative allosteric modulator Ro15-4513, further indicates that C-7 should be oriented towards a1H101, a2N102, [67]...
$\alpha_1$G157, $\alpha_1$V202, and $\alpha_1$V211, [68] also correlating with our model.

Available SAR data for BZDs indicate that the pending phenyl ring [pharmacophoric feature L3] is positioned in a narrow cavity [71,72]. Substitution at the ring is only tolerated in the 2'-position, whereas substitution in positions 3' and 4' are poorly tolerated. [71,72] Our model agrees with these observations, as the pending phenyl ring is positioned in an aromatic box formed by $\alpha_1$F99, $\alpha_1$H101, $\alpha_1$Y159, $\gamma_2$F99, and $\gamma_2$N128. In addition to satisfying ligand requirements of aromatic burial, the described position of the pending phenyl ring also serves as a strong contact point between the $\alpha_1$ and the $\gamma_2$ subunits.

The remaining lipophilic pharmacophoric features L3 (corresponding to the phenyl group in DZP) and L4L of the traditional benzodiazepine pharmacophore models [14,71,103] are situated near residues $\alpha_1$V202 and $\alpha_1$V211, and $\gamma_2$A79, $\gamma_2$L140, $\gamma_2$Y58, $\gamma_2$Q56, respectively. The latter feature is not occupied by DZP but is important for binding and function of other BZD binding site ligands, e.g. n-desf-3-yl-glyoxylandmides [106].

An additional point of inter subunit contact is the carbonyl group of DZP. This carbonyl is positioned under the tip of the C-loop and it is in an optimal position to form hydrogen bonds across the interface through $\alpha_1$T206 and $\gamma_2$T142, similar to how the GABA carboxylate binds to $\beta_2$T202 and $\alpha_1$T129 in the orthosteric binding site. Indeed, mutation of $\alpha_1$T206 has been identified in several studies to severely affect binding affinity of BZDs (Table 2).

Further interactions between DZP and the receptor model are formed by the polarized $\alpha$-methyl group. Due to the position of the methyl group on a nitrogen atom, the hydrogen atoms are more polarized than they would be if the methyl group was attached to an aliphatic carbon, thereby being able to form polar contacts with the receptor. This has been seen previously in AChBP X-ray structures [94]. In our model these hydrogen atoms are positioned in the negatively charged electrostatic field of the backbone carbonyl oxygen of $\alpha_1$Y159 and the hydroxyl groups of $\alpha_1$T206 and $\alpha_1$Y209. This also explains the beneficial effect of including the $\alpha$-methyl substituent in BZDs. [72]

Interestingly, when comparing the validated binding modes of GABA and DZP in their respective binding sites it is intriguing to see that corresponding residues, in particular $\beta_2$T202/$\alpha_1$T206, $\beta_2$Y205/$\alpha_1$Y209, $\beta_2$Y97/$\alpha_1$F99, $\beta_2$Y157/$\alpha_1$Y159, $\alpha_1$T129/$\gamma_2$T142 and $\gamma_2$F64/$\gamma_2$F77 are responsible for contacts between receptor and ligands and that both GABA and DZP in a similar manner bridge neighboring subunits. We have recently shown that a third binding site exists in the $\alpha_1$$\gamma_2$ interface of the so-called low sensitivity nAChR (92,93) and hypothesized that this could be the nicotinic pendant of the BZD binding site [107]. The structural model presented here may help to design experiments to investigate this hypothesis and thus contribute to the ongoing debate of the mechanism of action of BZDs [96,98,108–111].

**Conclusions**

The model and subsequent validation by available experimental data shows that reliable GABA,\textsubscript{R} models can be obtained using novel full length receptor templates. In addition to serving as a model of how agonists and modulators may bind to the GABA,\textsubscript{R}, the model may help to guide mutational studies unraveling the mechanism by which agonists, BZDs and other allosteric modulators work.

Compared to earlier templates used for homology modeling of the GABA,\textsubscript{R}s the emergence of the X-ray structure of the GluCl ion channel has significantly increased the insight into the architecture of anionic Cys-Loop receptors. With the new templates, sequence identities with respect to GABA sequences are as high as 36% and even up to 48% if narrowing the focus to the Cys-Loop receptor family has now improved considerably. Previously published homology models have mainly been modeled with AChBP as template. With sequence identities as low as 19% combined with the lack of a TMD as is the case when using AChBPs as templates, homology models based on the GluCl structure represents a big step forward.

Figure 8. DZP binding mode. A) The assumed biologically active binding mode of DZP (gray) at the interface between the $\alpha_1$ (smudge) and $\gamma_2$ (firebrick) subunits. In this conformation the C-3 points upwards and the pending phenyl substituent is directed inwards. B) Covalently attached DZP-NCS (cyan) overlaid with DZP (gray). Only moderate differences between the docked and the covalently attached ligands exist. doi:10.1371/journal.pone.0052323.g008
Based on homology modeling, advanced docking methods, QM calculations and a vast amount of collected experimental data, we have identified binding hypotheses for GABA_A, muscimol, THIP and diazepam and optimized the binding sites accordingly. Our GABA_AR model is modeled in the open state according to the GluCl glutamate bound structure and is intended for creating binding hypotheses of agonists or BZD site modulators. The model is made available in Model S1.

Supporting Information

Model S1 The GABA_AR model described in this paper.

References

8. Grant JA, Bonnick T, Gossell-Williams M, Clayton T, Cook JM, et al. (2010) Pharmacophore/receptor models for GABA_A/BzR alpha(2)beta(2)gamma(2) and beta(2)gamma(2)recombinant subtypes. Volume included analysis and comparison to alpha(2)beta(2)gamma(2) and alpha(2)beta(2)gamma(2)drugs. Drug Discov Today 17: 131–171.

Figure S1 Calculations of binding site sequence identities. (PDF)

Figure S2 RMDS plot and details of a 48 ns molecular dynamics simulation. (PDF)

Author Contributions

Conceived and designed the experiments: RB KK PS TS TB. Performed the experiments: RB KK PS. Analyzed the data: RB KK PS TB. Wrote the paper: RB KK TS TB.


96. Hansson SM, Morlok EV, Satysahr KA, Czajkowski C (2009) Structural requirements for ezopiclone and zolpidem binding to the gamma-aminobutyric acid(C) receptor type A. Bioinformatics 25: 4718–4725.


